Please login to the form below

Not currently logged in
Email:
Password:

Eisai moves to end Aricept partnership

Eisai claims that it has the right to terminate the strategic alliance and development agreement with Pfizer for Aricept after the pharma giant's buyout of Wyeth

Eisai claims that it has the right to terminate the strategic alliance and development agreement with Pfizer for Aricept after the pharma giant's buyout of Wyeth. A tug of war is likely to ensue with Pfizer already denying that the Japanese drugmaker has any basis for this challenge.

The bone of contention and trigger for Eisai's claim appears to be Wyeth's in-pipeline Alzheimer's medications. When Pfizer announced its $68bn Wyeth buyout, it made an offhand reference to potential trouble with Eisai. This is the first real indication that the Japanese company wants out of the deal.

Aricept added $482m to Pfizer's top line in 2008, and the drug accounted for 38 per cent of Eisai's sales for the nine months ending December 31, 2008.

11th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics